| As
of December 2007:
AB5000
- >70 U. S. Centers
- Average duration of support > 21 Days
- Longest duration of support > 300 days
AB5000 - FDA Approved Indications for Use
The AB5000 indications for use encompass any cardiac
disorder, resulting in ventricular failure, where
assist is likely to allow native heart recovery. This
includes, but is not limited to: postcardiotomy shock,
failed cardiac transplant, right heart failure while
on an implantable left ventricular assist device,
and other cardiac conditions such as viral myocarditis.
FACT:
Emerging use of the AB5000 in the AMI-Cardiogenic
shock indication approaching 50% survival.
|